LHF-535 NEW
| Price | $39 | $64 | $97 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-11 |
Product Details
| Product Name: LHF-535 | CAS No.: 1450929-77-7 |
| Purity: 99.90% | Supply Ability: 10g |
| Release date: 2025/11/11 |
Product Introduction
Bioactivity
| Name | LHF-535 |
| Description | LHF-535 is an antiviral compound. It has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively. |
| In vitro | LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 inhibits Lassa GP-pseudotyped lentivirus (IC50: 0.1-0.3 nM). LHF-535 shows effective antiviral activity against a broad array of hemorrhagic fever arenaviruses [2]. |
| In vivo | An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection. LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protects mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (8 mM), Sonication is recommended. DMSO : 96.67 mg/mL (234.34 mM), Sonication is recommended. H2O : < 0.1 mg/mL (insoluble) |
| Keywords | VirusProtease | Virus Protease | LHF-535 | LHF535 | LHF 535 | Inhibitor | inhibit | Arenavirus | antiviral |
| Inhibitors Related | Dibenzofuran | Esculin | Phenytoin sodium | Levofloxacin hydrochloride | Hexane-2,5-dione | L-Lysine | Sodium formate | Penicillin G potassium | Ofloxacin | (E)-3-(p-Tolyl)acrylaldehyde | Thymidine | Naringenin |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY